Is ICCC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ICCC. It does not provide personalized investment advice.

ICCC (Immucell Corp) Stock Analysis - Financials

Immucell Corp (ICCC) is a publicly traded Healthcare sector company. As of October 12, 2026, ICCC trades at $9.80 with a market cap of $89.01M and a P/E ratio of 121.85. ICCC moved +2.55% today. Year to date, ICCC is +56.10%; over the trailing twelve months it is +41.18%. Its 52-week range spans $4.28 to $12.10. Rallies surfaces ICCC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are ICCC's key financials?

ICCC financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ICCC recently traded at $9.80. Market cap is $89.01M. P/E ratio is 121.85. Revenue is $30.68M.

ICCC Key Metrics

Key financial metrics for ICCC
Metric	Value
Price	$9.80
Market Cap	$89.01M
P/E Ratio	121.85
EPS	$0.08
Dividend Yield	0.00%
52-Week High	$12.10
52-Week Low	$4.28
Volume	8.50K
Avg Volume	0
Revenue (TTM)	$30.68M
Net Income	$787.37K
Gross Margin	40.32%

ICCC Analyst Consensus

ICCC analyst coverage data. Average price target: $0.00.

Common questions about ICCC

What are ICCC's key financials?: ICCC financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ICCC recently traded at $9.80. Market cap is $89.01M. P/E ratio is 121.85. Revenue is $30.68M.
Is ICCC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ICCC. It does not provide personalized investment advice.